Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...
Although significant progress has been made in the treatment and management of patients with FL, several challenges remain, including the need to develop better prognostic models and markers for ...
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...
INDIANAPOLIS, April 5, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals today announced encouraging preclinical results for its lead product candidate, SF1126, in certain B-cell malignancies. The ...
The Phase II OCULE-01 study in uveal melanoma started in March 2025, the PULMO-01 study in non-small cell lung cancer (NSCLC) started in May 2025 and the HEMA-MED Phase I/II study in myelofibrosis ...
SAN FRANCISCO -- In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) recurrence, according to a randomized study reported here.
Capecitabine (X) in the first-line treatment of metastatic breast cancer (MBC). Background: PI3K pathway alterations (receptor tyrosine kinase amplification, activating mutations of PIK3CA or PTEN ...
Andean highlanders adapt to thin air through epigenetic gene tuning, revealing a flexible, long-term path to altitude survival.
INDIANAPOLIS, May 26, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals today announced that Phase 1 clinical data for SF1126 will be presented at the 47th Annual Meeting of the American Society of ...
Immunotherapies have been successful in treating many cancer conditions; however, not much success has yet been achieved in metastatic castrate-resistant prostate cancer (mCRPC). A study published ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback